Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 6.7% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price was up 6.7% on Monday . The company traded as high as $15.90 and last traded at $13.89. Approximately 1,577,758 shares were traded during mid-day trading, an increase of 162% from the average daily volume of 602,501 shares. The stock had previously closed at $13.02.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm has a market cap of $25.47 million, a P/E ratio of 0.00 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock’s 50-day moving average is $20.40 and its 200 day moving average is $20.29.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals in the fourth quarter worth $72,000. Commonwealth Equity Services LLC acquired a new stake in Tonix Pharmaceuticals during the fourth quarter worth approximately $40,000. Geode Capital Management LLC boosted its holdings in shares of Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after acquiring an additional 1,855,907 shares during the period. Northern Trust Corp acquired a new position in shares of Tonix Pharmaceuticals in the fourth quarter valued at approximately $162,000. Finally, Jane Street Group LLC increased its stake in shares of Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock worth $548,000 after purchasing an additional 1,635,119 shares during the period. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.